Thrombolysis for acute ischaemic stroke;Trombolyse ved iskæmisk apopleksi

Ugeskrift for Laeger

Volumn 169, Issue 40, 2007, Pages 3383-3385

  Modrau, Boris ^a,b   Vestergaard, Karsten ^a   Iversen, Helle K ^a   Homburg, Anne Mette F ^a   Boysen, Gudrun ^a   Andersen, Grethe ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE DISEASE; ARTICLE; BRAIN ISCHEMIA; FIBRINOLYTIC THERAPY; HUMAN; STROKE;

ACUTE DISEASE; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY;

EID: 37049013540     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Overgaard K, Sperling B, Boysen G et al Thrombolytic therapy in acute ischaemic stroke. Stroke 1993;24:1439-46.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
3. Wardlaw JM, del Zoppo G, Yamaguchi T et al. Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD000213. DOI: 10.1002/14651858.CD000213.
4. The Atlantis, ECASS, and NINDS rt-PA Study Group Investigation. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
5. Boysen G, Vorstrup S, Meden P et al. Trombolysebehandling af akut cerebralt infarct. Ugeskr Læger 2001;163:4741-4.
6. Reeves MJ, Arora S, Broderick JP et al. Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from the 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005;36:1232-40.
7. Bech M, Ehlers L, Andersen G et al. Medicinsk teknologivurdering af trombolysebehandling af apopleksipatienter MTV-enheden ved Århus Universitetshospital. Århus Amt, Afdeling for Folkesundhed, 2005.
8. Furlan AJ, Gregory DE, Albers W et al for the DEDAS Investigators Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37;1227-31.
9. Hacke W, Albers G, Al-Rawi Y et al. for the DIAS Study Group. The Desmoteplase in Acute Tschemic Stroke Trial (DIAS). A phase II MRI-based 9-hour window acute ischemic stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
10. Alexandrov AV, Molina CA, Grotta JC et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-8.
11. Fisher M, Davalos A, Rogalewski A et al. Toward a multimodal neuroprotective treatment of stroke. Stroke 2006;37:1129-36.